+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Chemotherapy-induced Nausea and Vomiting Market - Global Opportunities and Forecast 2014-2022

  • ID: 4612576
  • Report
  • January 2017
  • Region: Global
  • 70 pages
  • Allied Analytics LLP
Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer.

The global Chemotherapy-induced Nausea and Vomiting market was valued at $1,663 million in 2015, and is estimated to reach $2, 659 million by 2022, registering a CAGR of 7.1% during the forecast period. At present, pharmaceutical companies are increasingly investing in the further discovery of CINV drugs through focused clinical research studies. Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016 approximately 1.6 million new cases of cancer will be diagnosed with breast, lung and bronchus cancer as most common along all the types in addition to existing number of cancer patients.

The global CINV market is segmented into patient pool type and geography. The patient pool type is segmented into namely Aloxi (palonosetron), Kytril Generic (Granisetron), Emend (aprepitant), Netupitant-Palonosetron FDC and Others. Among the segments, the Netupitant Palonosetron market is expected to witness the fastest growth, globally during the forecast period 2016-2022.

Based on geography, the global CINV market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share (nearly half) in the global chemotherapy-induced nausea and vomiting market in 2015 due to growth in demand for CINV drugs due to the rise in number of patients undergoing chemotherapy, introduction of novel delivery methods to improve patient compliance. However, Asian region is expected to grow at a fastest CAGR during the forecast period, owing to large CINV patient pool and huge demand for the Netupitant–Palonosetron from these patients. Netupitant - Palonosetron is one of the first forms of fixed dose combination, which is approved for treating chemotherapy-induced nausea and vomiting that is likely to drive this market in the near future.


The study provides in-depth analysis of the CINV market along with the current trends and future estimations to elucidate the imminent investment pockets.
The study provides analysis of key market dynamics, which influence the adoption of CINV drugs
The report provides a quantitative analysis for the period of 2014–2022 to enable stakeholders to capitalize on the prevailing opportunities in the industry.
Extensive analysis of the global market helps understand cancer inducing Nausea and vomiting drugs developed and marketed by the key companies.
Competitive intelligence of market players highlights the business practices and trends across various regions.


Patient Pool Type

Aloxi, Kytril

By Geography

North America
Rest of Europe
Rest of Asia-Pacific
Latin America
Middle East


GlaxoSmithKline plc
Helsinn Holding S.A.
Heron Therapeutics, Inc.
Merck & Co., Inc.
Tesaro, Inc
Note: Product cover images may vary from those shown
1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst Tools and Models

2.1 CXO Perspective

3.1 Market Definition and Scope
3.2 Key Findings
3.2.1 Top Impacting Factors
3.2.2 Top Investment Pockets
3.3 Porters Five Force Analysis
3.4 Drivers
3.4.1 Growing Number of patients undergoing Chemotherapy
3.4.2 Growing research and development efforts in order to discover a universal antiemetic therapy
3.4.3 Introduction of novel delivery methods to improve patient compliance.
3.4.4 Advancements in technology to discover new potential drug targets
3.5 Restrains
3.5.1 Increasing side effects of CINV drugs
3.5.2 High cost associated with the new drug discovery and in developing regions.
3.6 Opportunities
3.6.1 Efficacy of combination therapy is expected to improve.
3.6.2 Improved quality of life for patients with cancer.
3.7 Market Trends

4.1 Overview
4.2 Netupitant-Palonosetron FDC
4.2.1 Key market trends
4.2.2 Key growth factors & opportunities
4.2.3 Market size & forecasts
4.3 Aloxi (palonosetron)
4.3.1 Key market trends
4.3.2 Key growth factors & opportunities
4.3.3 Market size & forecasts
4.4 Kytril Generic (Granisetron)
4.4.1 Key market trends
4.4.2 Key growth factors & opportunities
4.4.3 Market size & forecasts
4.5 Emend (aprepitant)
4.5.1 Key market trends
4.5.2 Key growth factors & opportunities
4.5.3 Market size & forecasts

5.1 North America
5.1.1 Key Market Trends
5.1.2 Key Growth Factors and Opportunities
5.1.3 Market Size and Forecast
5.2 Europe
5.2.1 Key Market Trends
5.2.2 Key Growth Factors and Opportunities
5.2.3 Market Size and Forecast
5.3 Asia-Pacific
5.3.1 Key Market Trends
5.3.2 Key Growth Factors and Opportunities
5.3.3 Market Size and Forecast
5.4 Latin America, Middle East and Africa (LAMEA)
5.4.1 Key Market Trends
5.4.2 Key Growth Factors and Opportunities
5.4.3 Market Size and Forecast

6.1 Helsinn Holding S.A.
6.1.1 Company Overview
6.1.2 Key Strategies and Developments
6.1.3 SWOT Analysis
6.2 Heron Therapeutics, Inc.
6.2.1 Company Overview
6.2.2 Business Performance
6.2.3 Key Strategies and Developments
6.2.4 SWOT Analysis
6.3 Merck & Co., Inc
6.3.1 Company Overview
6.3.2 Business Performance
6.3.3 Key Strategies and Developments
6.3.4 SWOT Analysis
6.4 GlaxoSmithKline plc
6.4.1 Company Overview
6.4.2 Business Performance
6.4.3 Key Strategies and Developments
6.4.4 Key Strategies and Developments
6.4.5 SWOT Analysis
6.5 Cadila Pharmaceuticals Limited
6.5.1 Company Overview
6.5.2 Business Performance
6.5.3 Key Strategies and Developments
6.5.4 Key Strategies and Developments
6.5.5 SWOT Analysis
6.6 Amneal Pharmaceuticals
6.6.1 Company Overview
6.6.2 Business Performance
6.6.3 Key Strategies and Developments
6.6.4 Key Strategies and Developments
6.6.5 SWOT Analysis
6.7 Kyowa Kirin, Inc.
6.7.1 Company Overview
6.7.2 Business Performance
6.7.3 Key Strategies and Developments
6.7.4 Key Strategies and Developments
6.7.5 SWOT Analysis
6.8 Acacia Pharma
6.8.1 Company Overview
6.8.2 Business Performance
6.8.3 Key Strategies and Developments
6.8.4 Key Strategies and Developments
6.8.5 SWOT Analysis
6.9 Insys Therapeutics, Inc
6.9.1 Company Overview
6.9.2 Business Performance
6.9.3 Key Strategies and Developments
6.9.4 Key Strategies and Developments
6.9.5 SWOT Analysis
6.10 Tesaro, Inc.
6.10.1 Company Overview
6.10.2 Business Performance
6.10.3 Key Strategies and Developments
6.10.4 Key Strategies and Developments
6.10.5 SWOT Analysis
*Details on financial performance, strategic moves and developments and SWOT analysis may not be captured for unlisted companies.
Note: Product cover images may vary from those shown
Chemotherapy-induced usea and Vomiting (CINV) Market report, forecasts that the global market is expected to garner $2,659 million by 2022, growing at a CAGR of 7.1% during 2016-2022.

Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with breast, lung, and bronchus cancer. It is observed that approximately 35% of patients experienced usea within 24 hours of chemotherapy, while 54% suffered from usea and 34% experienced vomiting after 24 hours.
Growth in number of patients undergoing chemotherapy drugs treatment and introduction of new drug delivery methods to improve patient compliance are the major factors that significantly impact the growth of the CINV market. At present, pharmaceutical companies are increasingly investing in the R&D of CINV drugs to offer better chemotherapy drugs and increase their market share.
According to Sriram Radhakrishn (Team Lead, Healthcare Research) at Allied Market Research, The needle free, painless, and cost-effective transdermal delivery system is expected to witness increase in demand in global CINV market.


The Aloxi segment generated highest revenue in the global market in 2015, accounting for over half of the total market.
The Netupitant-Palonosetron FDC segment is the fastest growing segment at a CAGR of 10.8%.
The North American market has witnessed a significant growth in the recent years. Presently, it is the largest regiol market for CINV drugs and an its market share is anticipated by 2022. Asia-Pacific is the fastest growing market due to increase in number of cancer population, high incidences of gastroenteritis and other diseases that lead to usea and vomiting. This region boosts up the demand for antiemetic drug due to growth in demand for CINV drugs and is expected to fuel the market growth in this region.
Partnership and collaboration is the key strategy adopted by companies to strengthen their position in the market.

The key major players in the global chemotherapy-induced usea and vomiting drugs are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.